baclofen and Gastroesophageal Reflux studies

Gastroesophageal Reflux: Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.

Research Excerpts

Excerpt	Relevance	Reference
"Gabapentin and baclofen have similar therapeutic efficacy for suspected refractory gastro-oesophageal reflux-induced chronic cough."	9.30	Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. ( Chen, Q; Ding, H; Dong, R; Lv, H; Pan, J; Qiu, Z; Shi, C; Xu, X; Yu, L; Yu, Y; Zhang, M, 2019)
"Arbaclofen placarbil is a pro-drug of the gamma-aminobutyric acid-B agonist R-baclofen that has been shown to reduce reflux episodes in patients with gastro-oesophageal reflux disease (GERD)."	9.17	Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. ( Cundy, KC; Huff, FJ; Vakil, NB, 2013)
"Baclofen, a GABA(B) agonist, has been shown to reduce transient lower oesophageal sphincter relaxations (TLESRs), a major cause of gastro-oesophageal reflux disease (GERD)."	9.16	Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study. ( Armbruster, SP; Cossentino, MJ; Lake, JM; Mann, K; Maydonovitch, C; Wong, RK, 2012)
"Baclofen, a GABA(b) agonist, has been shown to reduce episodes of gastroesophageal reflux (GER)."	9.16	The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. ( Goodrich, S; Mellow, M; Orr, WC; Shepherd, K; Wright, S, 2012)
"To evaluate the effect of baclofen, a gamma-amino-butyric-acid B receptor agonist that inhibits transient lower esophageal sphincter relaxation (TLESR), on the rates of TLESR, gastroesophageal reflux (GER), and gastric emptying (GE) in children with GER disease."	9.12	Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. ( Benninga, MA; Butler, RN; Davidson, GP; Dent, J; Omari, TI; Sansom, L, 2006)
"The GABA(B) receptor agonist baclofen improves duodenal reflux and associated reflux symptoms that persist during PPI therapy."	9.10	Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. ( Janssens, J; Koek, GH; Lerut, T; Sifrim, D; Tack, J, 2003)
"The GABA(B) agonist baclofen reduces 24 hour gastro-oesophageal reflux and increases gastric pH in GORD patients and controls."	9.10	Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. ( Ciccaglione, AF; Marzio, L, 2003)
"Baclofen decreases gastro-oesophageal reflux episodes in healthy subjects by reducing the incidence of transient lower oesophageal sphincter relaxations."	9.10	The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. ( Rydholm, H; Samsom, M; Smout, AJ; van Herwaarden, MA, 2002)
"Nine healthy volunteers and nine heartburn patients underwent two 2-h studies of combined MII/pH in right lateral decubitus after a refluxogenic meal in random order: on placebo and after baclofen 40 mg p."	9.10	Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. ( Castell, DO; Katz, PO; Tutuian, R; Vela, MF, 2003)
"In patients with reflux disease, the GABA(B) agonist baclofen significantly inhibits gastro-oesophageal reflux episodes by inhibition of TLOSRs."	9.10	Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. ( Dent, J; Holloway, RH; Lehmann, A; Rigda, R; Zhang, Q, 2002)
"Therapeutic efficacy of baclofen is suboptimal in the treatment of refractory gastroesophageal reflux-induced chronic cough (GERC)."	8.02	Pressure and length of the lower esophageal sphincter as predictive indicators of therapeutic efficacy of baclofen for refractory gastroesophageal reflux-induced chronic cough. ( Qiu, Z; Si, F; Sun, H; Xu, X; Yu, L; Zhang, M; Zhu, Y, 2021)
"To evaluate the efficacy and safety of baclofen for treatment of refractory gastroesophageal reflux-induced chronic cough (GERC) unresponsive to standard anti-reflux therapy."	7.79	Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough. ( Chen, Q; Liang, SW; Lv, HJ; Qiu, ZM; Xu, XH; Yang, ZM; Yu, L, 2013)
"In this 1-week trial, repetitive administration of baclofen reduced the frequency of emesis and the total number of acid refluxes in neurologically impaired children with GERD."	7.72	Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. ( Hirayama, S; Ida, S; Kawahara, H; Kawai, M; Yoshimura, N, 2004)
"Patients with persisting typical GERD symptoms on b."	7.11	Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms. ( Boecxstaens, V; Broers, C; Geeraerts, A; Masuy, I; Pauwels, A; Raymenants, K; Tack, J; Vanuytsel, T, 2022)
"Postprandial gastroesophageal reflux (PGER) in the distal esophagus (DE) is associated with a gastric juice 'acid pocket' (AP)."	6.82	Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. ( Boecxstaens, V; Broers, C; Pauwels, A; Scarpellini, E; Tack, J; Vos, R, 2016)
"Enrolled patients had GERD symptoms at least three times a week and 20 reflux episodes on impedance/pH monitoring over a period of 2 h."	6.75	Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. ( Agrawal, A; Castell, D; Gerson, LB; Hila, A; Hirota, WK; Huff, FJ; Lal, R; Luo, W; Reilley, S, 2010)
"Baclofen is a g-aminobutyric acid (GABA) derivative that inhibits the production of TLESRs by acting as a GABA(B) receptor agonist at one or more loci along the vagovagal reflex arc."	6.42	Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel? ( Conklin, JL; Wise, J, 2004)
" Dosing according to clearly defined age groups with the help of therapeutic drug monitoring seems preferable."	5.32	Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. ( Benninga, MA; Butter, JJ; Omari, T; van Aalderen, WM; van Boxtel, CJ; Wiersma, HE, 2003)
"Patients who were referred to Veterans Affairs (VA) gastroenterology clinics for PPI-refractory heartburn received 20 mg of omeprazole twice daily for 2 weeks, and those with persistent heartburn underwent endoscopy, esophageal biopsy, esophageal manometry, and multichannel intraluminal impedance-pH monitoring."	5.30	Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. ( Biswas, K; Castell, DO; Chan, BS; Chey, WD; Davis-Karim, A; Dunbar, KB; Fernando, RS; Gellad, ZF; Genta, RM; Ghaferi, AA; Huang, GD; Hunter, JG; Jackson, CS; Jones, KM; Kaz, AM; Kim, AW; Kim, T; Lagoo-Deenadayalan, S; Laine, L; Lee, R; Lieberman, D; Lo, WK; Mashimo, H; Melton, SD; Murthy, UK; Paski, SC; Pearl, JP; Pham, TH; Provenzale, D; Rubenstein, JH; Sanchez, VM; Serpi, T; Smith, BR; Souza, RF; Spechler, SJ; Tatum, RP; von Rosenvinge, EC; Wallen, JM; Warren, SR, 2019)
"Gabapentin and baclofen have similar therapeutic efficacy for suspected refractory gastro-oesophageal reflux-induced chronic cough."	5.30	Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. ( Chen, Q; Ding, H; Dong, R; Lv, H; Pan, J; Qiu, Z; Shi, C; Xu, X; Yu, L; Yu, Y; Zhang, M, 2019)
"Arbaclofen placarbil is a pro-drug of the gamma-aminobutyric acid-B agonist R-baclofen that has been shown to reduce reflux episodes in patients with gastro-oesophageal reflux disease (GERD)."	5.17	Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. ( Cundy, KC; Huff, FJ; Vakil, NB, 2013)
"Baclofen, a GABA(B) agonist, has been shown to reduce transient lower oesophageal sphincter relaxations (TLESRs), a major cause of gastro-oesophageal reflux disease (GERD)."	5.16	Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study. ( Armbruster, SP; Cossentino, MJ; Lake, JM; Mann, K; Maydonovitch, C; Wong, RK, 2012)
"It has been shown that arbaclofen placarbil (AP) inhibits reflux in gastroesophageal reflux disease (GERD) following single oral dosing."	5.15	Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. ( Bian, A; Huff, FJ; Jones, DS; Stamler, D; Vakil, NB, 2011)
"Reflux inhibitors, like the gamma-aminobutyric acid type B (GABA(B)) receptor agonist, baclofen, block transient lower esophageal sphincter relaxations (TLESRs) and are proposed as an add-on therapy in patients with proton pump inhibitor (PPI)-resistant gastroesophageal reflux."	5.14	Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? ( Beaumont, H; Boeckxstaens, GE, 2009)
"To explore the effect of baclofen on oesophageal acid exposure in patients with gastro-oesophageal reflux disease."	5.10	Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. ( Cange, L; Finizia, C; Johnsson, E; Lehmann, A; Lundell, L; Ruth, M; Rydholm, H, 2002)
"The GABA(B) receptor agonist baclofen improves duodenal reflux and associated reflux symptoms that persist during PPI therapy."	5.10	Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. ( Janssens, J; Koek, GH; Lerut, T; Sifrim, D; Tack, J, 2003)
"The GABA(B) agonist baclofen reduces 24 hour gastro-oesophageal reflux and increases gastric pH in GORD patients and controls."	5.10	Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. ( Ciccaglione, AF; Marzio, L, 2003)
"Nine healthy volunteers and nine heartburn patients underwent two 2-h studies of combined MII/pH in right lateral decubitus after a refluxogenic meal in random order: on placebo and after baclofen 40 mg p."	5.10	Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. ( Castell, DO; Katz, PO; Tutuian, R; Vela, MF, 2003)
"Baclofen decreases gastro-oesophageal reflux episodes in healthy subjects by reducing the incidence of transient lower oesophageal sphincter relaxations."	5.10	The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. ( Rydholm, H; Samsom, M; Smout, AJ; van Herwaarden, MA, 2002)
"In patients with reflux disease, the GABA(B) agonist baclofen significantly inhibits gastro-oesophageal reflux episodes by inhibition of TLOSRs."	5.10	Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. ( Dent, J; Holloway, RH; Lehmann, A; Rigda, R; Zhang, Q, 2002)
"In normal human subjects, the GABA(B) agonist baclofen significantly inhibits gastroesophageal reflux by inhibition of transient LES relaxations."	5.09	Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. ( Checklin, H; Dent, J; Holloway, RH; Lehmann, A; Lidums, I, 2000)
" The systematic review included medical trials written in English which were published between 2000 and 2016 and were retrieved from PubMed and Scopus using the keywords 'PPI-resistant gastro-oesophageal reflux', 'alginate AND gastro-oesophageal reflux', 'hyaluronic acid AND gastro-oesophageal reflux', 'prokinetics AND gastro-oesophageal reflux', 'sucralfate AND gastro-oesophageal reflux' and 'baclofen AND gastro-oesophageal reflux'."	4.98	Treatment of PPI-resistant gastro-oesophageal reflux: A systematic review. ( Gallusi, G; Pontone, S, 2018)
"Therapeutic efficacy of baclofen is suboptimal in the treatment of refractory gastroesophageal reflux-induced chronic cough (GERC)."	4.02	Pressure and length of the lower esophageal sphincter as predictive indicators of therapeutic efficacy of baclofen for refractory gastroesophageal reflux-induced chronic cough. ( Qiu, Z; Si, F; Sun, H; Xu, X; Yu, L; Zhang, M; Zhu, Y, 2021)
"This is the first case report describing a laparoscopic fundoplication in a child with an intrathecal Baclofen pump which was inserted because of severe spasticity secondary to cerebral palsy."	3.96	Laparoscopic fundoplication for a child with abdominal intrathecal Baclofen pump. ( Aida, Y; Bitoh, Y; Miyauchi, H; Nakatani, T; Okata, Y; Tomioka, Y, 2020)
"Non-acid GERC had the similar cough character, cough symptom score, and capsaicin cough sensitivity to acid GERC."	3.81	Comparison of clinical characteristics of chronic cough due to non-acid and acid gastroesophageal reflux. ( Chen, Q; Liang, S; Lü, H; Qiu, Z; Xu, X; Yang, Z; Yu, L, 2015)
"The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the role for ketamine and other alternative treatments in esophageal disorders; the use of linaclotide in the treatment of esophageal pain; the alginate test as a diagnostic criterion in gastroesophageal reflux disease (GERD); the use of baclofen in treatment of GERD; the effects of opioids on the esophagus; the use of antagonists on the receptor level in GERD; the effect of local formulation of drugs on the esophageal mucosa; and the use of electroencephalographic fingerprints to predict the effect of pharmacological treatment."	3.80	Pharmacologic treatments for esophageal disorders. ( Blackshaw, LA; Bordin, DS; Brock, C; Brokjaer, A; Drewes, AM; Farmer, AD; Krarup, AL; Lottrup, C; Masharova, AA; Moawad, FJ; Olesen, AE, 2014)
"To evaluate the efficacy and safety of baclofen for treatment of refractory gastroesophageal reflux-induced chronic cough (GERC) unresponsive to standard anti-reflux therapy."	3.79	Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough. ( Chen, Q; Liang, SW; Lv, HJ; Qiu, ZM; Xu, XH; Yang, ZM; Yu, L, 2013)
"Baclofen, a γ-aminobutyric acid receptor agonist, has been shown to reduce the episodes of gastroesophageal reflux (GER) by reducing the incidence of transient lower esophageal sphincter relaxations."	3.79	Baclofen for the treatment of pediatric GERD. ( Dimmitt, RA; Hitch, MC; Thame, KA; Vadlamudi, NB, 2013)
"We have previously demonstrated that the prototypical GABA B receptor agonist baclofen inhibits transient lower esophageal sphincter relaxations (TLESRs), the most important mechanism for gastroesophageal reflux."	3.74	Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors. ( Alstermark, C; Amin, K; Dinn, SR; Elebring, T; Fitzpatrick, K; Fjellström, O; Geiss, WB; Gottfries, J; Guzzo, PR; Harding, JP; Holmén, A; Kothare, M; Lehmann, A; Mattsson, JP; Nilsson, K; Sundén, G; Swanson, M; von Unge, S; Woo, AM; Wyle, MJ; Zheng, X, 2008)
"In this 1-week trial, repetitive administration of baclofen reduced the frequency of emesis and the total number of acid refluxes in neurologically impaired children with GERD."	3.72	Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. ( Hirayama, S; Ida, S; Kawahara, H; Kawai, M; Yoshimura, N, 2004)
"Patients with persisting typical GERD symptoms on b."	3.11	Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms. ( Boecxstaens, V; Broers, C; Geeraerts, A; Masuy, I; Pauwels, A; Raymenants, K; Tack, J; Vanuytsel, T, 2022)
"Postprandial gastroesophageal reflux (PGER) in the distal esophagus (DE) is associated with a gastric juice 'acid pocket' (AP)."	2.82	Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. ( Boecxstaens, V; Broers, C; Pauwels, A; Scarpellini, E; Tack, J; Vos, R, 2016)
"Nocturnal gastroesophageal reflux symptoms have a major impact on sleep quality and are associated with complicated gastroesophageal reflux disease (GERD)."	2.82	Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux. ( Bredenoord, AJ; Fockens, P; Kuipers, T; Schuitenmaker, JM; Smout, AJPM, 2022)
"In both HVs and GERD patients, baclofen reduced the frequency of postprandial reflux events."	2.79	Effects of baclofen on the functional anatomy of the oesophago-gastric junction and proximal stomach in healthy volunteers and patients with GERD assessed by magnetic resonance imaging and high-resolution manometry: a randomised controlled double-blind st ( Banerjee, S; Boesiger, P; Curcic, J; Forras-Kaufman, Z; Fox, M; Fried, M; Hebbard, GS; Kaufman, E; Pal, A; Schwizer, A; Schwizer, W; Steingoetter, A, 2014)
"Enrolled patients had GERD symptoms at least three times a week and 20 reflux episodes on impedance/pH monitoring over a period of 2 h."	2.75	Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. ( Agrawal, A; Castell, D; Gerson, LB; Hila, A; Hirota, WK; Huff, FJ; Lal, R; Luo, W; Reilley, S, 2010)
"Baclofen was additionally administered to 7/13 patients, which did not lead to a remarkable reduction in reflux events."	2.74	High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease--a prospective pH-metry/impedance-controlled study. ( Bajbouj, M; Becker, V; Meining, A; Phillip, V; Schmid, RM; Wilhelm, D, 2009)
"Gastroesophageal reflux disease (GERD) is a common disorder, and empirical proton pump inhibitor (PPI) treatment is often the first step of management; however, up to 40% of patients remain symptomatic despite PPI treatment."	2.72	Optimal management of severe symptomatic gastroesophageal reflux disease. ( Talley, NJ; Zand Irani, M, 2021)
"Up to 40% of patients report persistent gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy."	2.55	A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. ( Berendsen, MA; Hillman, L; Pandolfino, JE; Thuluvath, AJ; Yadlapati, R, 2017)
"In up to 30% of patients with typical GERD symptoms (heartburn and/or regurgitation), acid-suppressive therapy does not provide clinical benefit."	2.53	Management of refractory typical GERD symptoms. ( Ang, D; De Santis, A; Pauwels, A; Scarpellini, E; Tack, J; Vanuytsel, T, 2016)
" Among these, PPIs are considered first-line treatment for the control of nighttime gastric acid secretion; however, the timing and dosing of PPI administration should be individualized for each patient."	2.49	Gastroesophageal reflux disease and sleep. ( Arakawa, T; Fass, R; Fujiwara, Y, 2013)
" Twice-daily dosing of PPI for inadequate gastric acid suppression and the administration of H2-receptor antagonist before bedtime for nocturnal acid reflux, is effective in most cases."	2.44	[Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor]. ( Iwakiri, K; Kawami, N; Kotoyori, M; Sakamoto, C; Sano, H; Tanaka, Y, 2007)
"The therapy of gastroesophageal reflux disease (GERD) is uncomplicated in most cases."	2.43	[Diagnosis and therapy of weakly-acid/non-acidic gastroesophageal reflux disease]. ( Bajbouj, M; Meining, A; Schmid, RM; Stein, HJ, 2005)
"Gastro-oesophageal reflux disease is a multifaceted and multifactorial disorder which results from the reflux of gastric contents into the oesophagus."	2.43	Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. ( Tack, J, 2006)
"Baclofen is a g-aminobutyric acid (GABA) derivative that inhibits the production of TLESRs by acting as a GABA(B) receptor agonist at one or more loci along the vagovagal reflex arc."	2.42	Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel? ( Conklin, JL; Wise, J, 2004)
"The diagnosis of extraesophageal reflux for most patients relies on history and laryngoscopic exam."	2.42	Contemporary diagnostic and management techniques for extraesophageal reflux disease. ( Merati, A; Meyer, TK; Olsen, E, 2004)
"Baclofen is a GABA(B) receptor agonist that is effective in inhibiting TLESR and reducing the number of reflux episodes, but is associated with significant central nervous system (CNS) side effects."	1.36	Beyond acid suppression: new pharmacologic approaches for treatment of GERD. ( Holloway, RH; Kuo, P, 2010)
"Lesogaberan (AZD3355) is a peripherally restricted GABAB receptor agonist with limited central nervous system activity that inhibits transient LES relaxation in dogs."	1.36	The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs. ( Brändén, L; Fredriksson, A; Harring, E; Jensen, J; Lehmann, A, 2010)
" Dosing according to clearly defined age groups with the help of therapeutic drug monitoring seems preferable."	1.32	Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. ( Benninga, MA; Butter, JJ; Omari, T; van Aalderen, WM; van Boxtel, CJ; Wiersma, HE, 2003)
" It is concluded that repeated dosing of baclofen leads to mild tolerance development in terms of the effects on transient lower esophageal sphincter relaxation, but that the tolerance is much less pronounced than that previously reported in other animal models."	1.31	Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog. ( Hansson-Brändén, L; Kärrberg, L; Lehmann, A, 2000)
"Chronic hiccup is a rare but potentially severe condition, that can be symptomatic of a variety of diseases, or idiopathic."	1.29	Baclofen therapy for chronic hiccup. ( Bizec, JL; Cabane, J; Derenne, JP; Guelaud, C; Similowski, T; Whitelaw, WA, 1995)

Research

Studies (75)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Number of Enrolled Participants With Achalasia

Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.

Number of Enrolled Participants With Anxiety and/or Depression

Number of Enrolled Participants With Aperistalsis

Number of Enrolled Participants With Belching Disorders

Number of Enrolled Participants With Candida Esophagitis.

Number of Enrolled Participants With Chronic Idiopathic Nausea

Number of Enrolled Participants With Cyclic Vomiting Syndrome

Number of Enrolled Participants With Distal Esophageal Spasm

Number of Enrolled Participants With Eosinophilic Esophagitis

Number of Enrolled Participants With Esophageal Ulceration.

Number of Enrolled Participants With Functional Bloating

Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin

Number of Enrolled Participants With Functional Diarrhea

Number of Enrolled Participants With Functional Dysphagia

Number of Enrolled Participants With Functional Gallbladder Disorder

Number of Enrolled Participants With Functional Heartburn

Number of Enrolled Participants With Functional Vomiting

Number of Enrolled Participants With Gastric Outlet Obstruction

Number of Enrolled Participants With Globus

Number of Enrolled Participants With Hypertensive Peristalsis

Number of Enrolled Participants With Ineffective Esophageal Motility

Number of Enrolled Participants With Irritable Bowel Syndrome

Number of Enrolled Participants With Jackhammer Esophagus

Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum

Number of Enrolled Participants With Nutcracker Esophagus

Number of Enrolled Participants With Rapid Contraction

Number of Enrolled Participants With Reflux Esophagus.

Number of Enrolled Participants With Unspecified Functional Bowel Disorder

Number of Enrolled Participants With Weak Peristalsis I

Number of Enrolled Participants With Weak Peristalsis II

Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (4.00)	18.2507
2000's	31 (41.33)	29.6817
2010's	31 (41.33)	24.3611
2020's	10 (13.33)	2.80

Authors	Studies
Alstermark, C	1
Amin, K	1
Dinn, SR	1
Elebring, T	1
Fjellström, O	1
Fitzpatrick, K	1
Geiss, WB	1
Gottfries, J	1
Guzzo, PR	1
Harding, JP	1
Holmén, A	1
Kothare, M	1
Lehmann, A	9
Mattsson, JP	1
Nilsson, K	1
Sundén, G	1
Swanson, M	1
von Unge, S	1
Woo, AM	1
Wyle, MJ	1
Zheng, X	1
Schuitenmaker, JM	1
Kuipers, T	1
Smout, AJPM	1
Fockens, P	1
Bredenoord, AJ	1
Pauwels, A	4
Raymenants, K	3
Geeraerts, A	1
Boecxstaens, V	3
Masuy, I	1
Broers, C	2
Vanuytsel, T	2
Tack, J	9
Katz, PO	2
Vandenbergh, J	1
Ribolsi, M	1
Savarino, E	1
Okata, Y	1
Bitoh, Y	1
Aida, Y	1
Miyauchi, H	1
Nakatani, T	1
Tomioka, Y	1
Spechler, SJ	1
Hunter, JG	1
Jones, KM	1
Lee, R	1
Smith, BR	1
Mashimo, H	1
Sanchez, VM	1
Dunbar, KB	1
Pham, TH	1
Murthy, UK	1
Kim, T	1
Jackson, CS	1
Wallen, JM	1
von Rosenvinge, EC	1
Pearl, JP	1
Laine, L	1
Kim, AW	1
Kaz, AM	1
Tatum, RP	1
Gellad, ZF	1
Lagoo-Deenadayalan, S	1
Rubenstein, JH	1
Ghaferi, AA	1
Lo, WK	1
Fernando, RS	1
Chan, BS	1
Paski, SC	1
Provenzale, D	1
Castell, DO	2
Lieberman, D	1
Souza, RF	1
Chey, WD	1
Warren, SR	1
Davis-Karim, A	1
Melton, SD	1
Genta, RM	1
Serpi, T	1
Biswas, K	1
Huang, GD	1
Reddy, CA	1
Watts, L	1
Baker, JR	1
Chen, JW	1
Talley, NJ	1
Zand Irani, M	1
Zhu, Y	1
Xu, X	4
Zhang, M	2
Si, F	1
Sun, H	1
Yu, L	5
Qiu, Z	4
Vaezi, MF	2
Pandolfino, JE	2
Vela, MF	2
Shaheen, NJ	1
Hillman, L	1
Yadlapati, R	1
Thuluvath, AJ	1
Berendsen, MA	1
Gallusi, G	1
Pontone, S	1
Dong, R	2
Ding, H	1
Pan, J	1
Yu, Y	1
Shi, C	1
Chen, Q	3
Lv, H	1
Naik, RD	1
Fujiwara, Y	1
Arakawa, T	1
Fass, R	2
Dutta, U	1
Armstrong, D	1
Vakil, NB	2
Huff, FJ	3
Cundy, KC	1
Vadlamudi, NB	1
Hitch, MC	1
Dimmitt, RA	1
Thame, KA	1
Xu, XH	1
Yang, ZM	1
Liang, SW	1
Lv, HJ	1
Qiu, ZM	1
Schroedl, RL	1
Di Lorenzo, C	1
Alioto, A	1
Scarpellini, E	3
Farré, R	1
Bisschops, R	1
Dewulf, D	1
Gasbarrini, A	1
Blondeau, K	1
Yang, Z	1
Liang, S	1
Lü, H	1
Curcic, J	2
Schwizer, A	1
Kaufman, E	1
Forras-Kaufman, Z	1
Banerjee, S	1
Pal, A	1
Hebbard, GS	1
Boesiger, P	1
Fried, M	1
Steingoetter, A	1
Schwizer, W	1
Fox, M	2
Blackshaw, LA	3
Bordin, DS	1
Brock, C	1
Brokjaer, A	1
Drewes, AM	1
Farmer, AD	1
Krarup, AL	1
Lottrup, C	1
Masharova, AA	1
Moawad, FJ	1
Olesen, AE	1
Vakil, N	1
Vos, R	1
Ang, D	1
De Santis, A	1
Boeckxstaens, GE	6
Beaumont, H	2
Bajbouj, M	2
Becker, V	1
Phillip, V	1
Wilhelm, D	1
Schmid, RM	2
Meining, A	2
Smout, A	1
Aanen, M	1
Rydholm, H	4
Lei, A	2
Ruth, M	4
Boeckxstaens, G	1
Gerson, LB	1
Hila, A	1
Hirota, WK	1
Reilley, S	1
Agrawal, A	1
Lal, R	1
Luo, W	1
Castell, D	1
Brändén, L	1
Fredriksson, A	1
Harring, E	1
Jensen, J	1
Adler, J	1
Kuo, P	1
Holloway, RH	3
Storr, MA	1
Bian, A	1
Jones, DS	1
Stamler, D	1
Denison, H	1
Jensen, JM	1
van der Pol, R	1
Benninga, MA	3
Smout, AJ	2
Orr, WC	1
Goodrich, S	1
Wright, S	1
Shepherd, K	1
Mellow, M	1
Cossentino, MJ	1
Mann, K	1
Armbruster, SP	1
Lake, JM	1
Maydonovitch, C	1
Wong, RK	1
van Herwaarden, MA	1
Samsom, M	1
Hasler, WL	1
Richter, JE	1
Tutuian, R	1
Wiersma, HE	1
van Boxtel, CJ	1
Butter, JJ	1
van Aalderen, WM	1
Omari, T	1
Ciccaglione, AF	1
Marzio, L	2
Rosen, R	1
Nurko, S	1
Furuta, GT	1
Koek, GH	1
Sifrim, D	2
Lerut, T	1
Janssens, J	1
Kawai, M	1
Kawahara, H	1
Hirayama, S	1
Yoshimura, N	1
Ida, S	1
Wise, J	1
Conklin, JL	1
Meyer, TK	1
Olsen, E	1
Merati, A	1
Stein, HJ	1
Omari, TI	1
Sansom, L	1
Butler, RN	1
Dent, J	5
Davidson, GP	1
Iwakiri, K	1
Kawami, N	1
Tanaka, Y	1
Sano, H	1
Kotoyori, M	1
Sakamoto, C	1
Coron, E	1
Hatlebakk, JG	1
Galmiche, JP	1
Grossi, L	1
Spezzaferro, M	1
Sacco, LF	1
Guelaud, C	1
Similowski, T	1
Bizec, JL	1
Cabane, J	1
Whitelaw, WA	1
Derenne, JP	1
Staunton, E	2
Lidums, I	1
Checklin, H	1
Smid, SD	1
Hansson-Brändén, L	1
Kärrberg, L	1
Zhang, Q	1
Rigda, R	1
Hirsch, DP	1
Tytgat, GN	2
Cange, L	1
Johnsson, E	1
Finizia, C	1
Lundell, L	1
Zaninotto, G	1
Costantini, M	1
Ancona, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors[NCT01265550]	Phase 3	366 participants (Actual)	Interventional	2012-08-13	Completed
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program[NCT03719170]		208,266 participants (Actual)	Interventional	2019-09-16	Completed
Open, Comparative Study To Evaluate The Performance And Safety Of The Medical Device Marial® In Association With Proton-Pump Inhibitors Versus PPI Alone In Patients Affected By Gastroesophageal Reflux Disease[NCT04130659]		110 participants (Anticipated)	Interventional	2019-08-08	Recruiting
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)[NCT00978016]	Phase 2	460 participants (Actual)	Interventional	2009-09-30	Completed
Combined Scalp and Ear Acupuncture in Patients With Proton Pump Inhibitor- Dependent Gastroesophageal Reflux Disease[NCT04660019]		43 participants (Actual)	Interventional	2020-08-10	Completed
A Randomized Placebo Controlled Study of Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis[NCT02221570]		100 participants (Anticipated)	Interventional	2014-06-30	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
All Enrolled	2

Intervention	Participants (Count of Participants)
All Enrolled	3

Intervention	Participants (Count of Participants)
All Enrolled	125

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	130

Intervention	Participants (Count of Participants)
All Enrolled	3

Intervention	Participants (Count of Participants)
All Enrolled	51

Intervention	Participants (Count of Participants)
All Enrolled	86

Intervention	Participants (Count of Participants)
All Enrolled	3

Intervention	Participants (Count of Participants)
All Enrolled	16

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	8

Intervention	Participants (Count of Participants)
All Enrolled	13

Intervention	Participants (Count of Participants)
All Enrolled	4

Intervention	Participants (Count of Participants)
All Enrolled	7

Intervention	Participants (Count of Participants)
All Enrolled	1

Intervention	Participants (Count of Participants)
All Enrolled	221

Intervention	Participants (Count of Participants)
All Enrolled	32

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	3

Intervention	Participants (Count of Participants)
All Enrolled	1

Intervention	Participants (Count of Participants)
All Enrolled	152

Intervention	Participants (Count of Participants)
All Enrolled	8

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	2

Intervention	Participants (Count of Participants)
All Enrolled	2

Intervention	Participants (Count of Participants)
All Enrolled	4

Intervention	Participants (Count of Participants)
All Enrolled	56

Intervention	Participants (Count of Participants)
All Enrolled	10

Intervention	Participants (Count of Participants)
All Enrolled	9

"Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months.~Failure; <50% improvement in the baseline GERD-HRQL score at 12 months or:~For patients randomized to Surgical Treatment: a.<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit.~For patients randomized to Active Medical or Placebo Medical Treatment:~a.inability to tolerate both study medications or b.For patients treated with desipramine, i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit." (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Anxiety and/or Depression.

Intervention	Participants (Count of Participants)
Medical Treatment Group	7
Surgical Treatment Group	18
Placebo Medical Treatment Group	3

Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Belching Disorders

Intervention	Participants (Count of Participants)
Medical Treatment Group	2
Surgical Treatment Group	5
Placebo Medical Treatment Group	0

Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Chronic Idiopathic Nausea

Intervention	Participants (Count of Participants)
Medical Treatment Group	3
Surgical Treatment Group	12
Placebo Medical Treatment Group	2

Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Cyclic Vomiting Syndrome

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	3
Placebo Medical Treatment Group	0

Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Bloating

Intervention	Participants (Count of Participants)
Medical Treatment Group	1
Surgical Treatment Group	7
Placebo Medical Treatment Group	1

Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin

Intervention	Participants (Count of Participants)
Medical Treatment Group	1
Surgical Treatment Group	1
Placebo Medical Treatment Group	0

Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Diarrhea

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Dysphagia

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Gallbladder Disorder

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Heartburn

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Vomiting

Intervention	Participants (Count of Participants)
Medical Treatment Group	7
Surgical Treatment Group	14
Placebo Medical Treatment Group	3

Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Globus

Intervention	Participants (Count of Participants)
Medical Treatment Group	1
Surgical Treatment Group	1
Placebo Medical Treatment Group	1

Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Irritable Bowel Syndrome

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Unspecified Functional Bowel Disorder

Intervention	Participants (Count of Participants)
Medical Treatment Group	3
Surgical Treatment Group	10
Placebo Medical Treatment Group	3

Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Article	Year
Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux. Neurogastroenterology and motility, 2022, Volume: 34, Issue:12 Topics: Adult; Baclofen; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Hypnotics and Sedatives;	2022
Optimal management of severe symptomatic gastroesophageal reflux disease. Journal of internal medicine, 2021, Volume: 289, Issue:2 Topics: Alginates; Antidepressive Agents; Baclofen; Bile Acids and Salts; Breathing Exercises; Diagnosis, Di	2021
A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Sep-01, Volume: 30, Issue:9 Topics: Baclofen; Benzamides; Cytochrome P-450 CYP2C19; Esophageal Sphincter, Lower; Gastroesophageal Reflux	2017
Treatment of PPI-resistant gastro-oesophageal reflux: A systematic review. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2018, Volume: 19, Issue:2 Topics: Baclofen; Benzamides; Chondroitin Sulfates; Domperidone; Drug Combinations; Drug Therapy, Combinatio	2018
Gastroesophageal reflux disease and sleep. Gastroenterology clinics of North America, 2013, Volume: 42, Issue:1 Topics: Baclofen; Fundoplication; GABA-B Receptor Agonists; Gastroesophageal Reflux; Humans; Hypnotics and S	2013
Novel pharmaceutical approaches to reflux disease. Gastroenterology clinics of North America, 2013, Volume: 42, Issue:1 Topics: Alginates; Baclofen; Drug Therapy, Combination; GABA-B Receptor Agonists; Gastroesophageal Reflux; G	2013
Adolescent rumination syndrome. Pediatric annals, 2014, Volume: 43, Issue:4 Topics: Adolescent; Baclofen; Diagnosis, Differential; Feeding and Eating Disorders of Childhood; GABA-B Rec	2014
Management of refractory typical GERD symptoms. Nature reviews. Gastroenterology & hepatology, 2016, Volume: 13, Issue:5 Topics: Alginates; Algorithms; Antacids; Baclofen; Chronic Disease; Esophagoscopy; Gastroesophageal Reflux;	2016
Reflux inhibitors: a new approach for GERD? Current opinion in pharmacology, 2008, Volume: 8, Issue:6 Topics: Animals; Baclofen; Esophageal Sphincter, Lower; Esophagitis, Peptic; Gastroesophageal Reflux; Humans	2008
Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'. Current opinion in pharmacology, 2011, Volume: 11, Issue:6 Topics: Animals; Baclofen; Dogs; Drug Resistance; Esophageal Sphincter, Lower; GABA-B Receptor Agonists; Gas	2011
Emerging therapies for GERD. Journal of pediatric gastroenterology and nutrition, 2011, Volume: 53 Suppl 2 Topics: Baclofen; GABA-B Receptor Agonists; Gastroesophageal Reflux; Humans; Phosphinic Acids; Propylamines;	2011
Novel medical therapies for gastroesophageal reflux disease beyond proton-pump inhibitors. Gastroenterology clinics of North America, 2002, Volume: 31, Issue:4 Suppl Topics: Atropine; Baclofen; Computer Graphics; Drug Therapy, Combination; GABA Agonists; Gastroesophageal Re	2002
Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel? Current gastroenterology reports, 2004, Volume: 6, Issue:3 Topics: Animals; Baclofen; Esophagogastric Junction; GABA Agonists; Gastroesophageal Reflux; Humans; Manomet	2004
Contemporary diagnostic and management techniques for extraesophageal reflux disease. Current opinion in otolaryngology & head and neck surgery, 2004, Volume: 12, Issue:6 Topics: Baclofen; Child; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Humans; Muscle Relaxants, Cen	2004
[Diagnosis and therapy of weakly-acid/non-acidic gastroesophageal reflux disease]. Deutsche medizinische Wochenschrift (1946), 2005, Oct-07, Volume: 130, Issue:40 Topics: Baclofen; Electric Impedance; Esophagoscopy; Esophagus; Fundoplication; GABA Agonists; Gastroesophag	2005
Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 2006, Volume: 24 Suppl 2 Topics: Animals; Baclofen; Bile; Bile Acids and Salts; Drug Synergism; Duodenum; Esophageal Diseases; Esopha	2006
[Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:5 Topics: Aryl Hydrocarbon Hydroxylases; Baclofen; Cytochrome P-450 CYP2C19; Diet; Drug Administration Schedul	2007
Medical therapy of gastroesophageal reflux disease. Current opinion in gastroenterology, 2007, Volume: 23, Issue:4 Topics: Anti-Ulcer Agents; Baclofen; Exercise; Fruit; Gastroesophageal Reflux; Humans; Indoles; Life Style;	2007
Transient lower oesophageal sphincter relaxations--a pharmacological target for gastro-oesophageal reflux disease? Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:1 Topics: Atropine; Baclofen; Endoscopy, Gastrointestinal; Esophagogastric Junction; Fundoplication; GABA Agon	2002

Article	Year
Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms. Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:2 Topics: Adult; Aged; Baclofen; Double-Blind Method; Esophageal pH Monitoring; Gastroesophageal Reflux; Human	2022
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16 Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga	2019
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16 Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga	2019
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16 Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga	2019
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16 Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga	2019
Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:6 Topics: Adult; Analgesics; Baclofen; Chronic Disease; Cough; Dose-Response Relationship, Drug; Female; Follo	2019
Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:2 Topics: Adult; Baclofen; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esoph	2013
Effects of baclofen on the functional anatomy of the oesophago-gastric junction and proximal stomach in healthy volunteers and patients with GERD assessed by magnetic resonance imaging and high-resolution manometry: a randomised controlled double-blind st Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:10 Topics: Adult; Baclofen; Cross-Over Studies; Double-Blind Method; Esophageal Sphincter, Lower; Female; GABA-	2014
Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2016, Volume: 29, Issue:8 Topics: Adult; Baclofen; Double-Blind Method; Drug Administration Schedule; Esophageal Sphincter, Lower; Eso	2016
Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? The American journal of gastroenterology, 2009, Volume: 104, Issue:7 Topics: Adult; Aged; Analysis of Variance; Baclofen; Cross-Over Studies; Dose-Response Relationship, Drug; D	2009
High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease--a prospective pH-metry/impedance-controlled study. Digestion, 2009, Volume: 80, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Baclofen; Cohort Studies; Dose-Response Relationship, Drug; Drug Adm	2009
The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Alimentary pharmacology & therapeutics, 2009, Nov-01, Volume: 30, Issue:9 Topics: Adult; Baclofen; Cross-Over Studies; Dose-Response Relationship, Drug; Esophageal Sphincter, Lower;	2009
Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. The American journal of gastroenterology, 2010, Volume: 105, Issue:6 Topics: Adult; Baclofen; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Esophage	2010
Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:11 Topics: Adolescent; Adult; Baclofen; Cross-Over Studies; Esophageal Sphincter, Lower; GABA Agonists; Gastroe	2010
Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. The American journal of gastroenterology, 2011, Volume: 106, Issue:8 Topics: Adult; Aged; Baclofen; Dizziness; Double-Blind Method; Drug Administration Schedule; Fatigue; Female	2011
The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. Neurogastroenterology and motility, 2012, Volume: 24, Issue:6 Topics: Adult; Aged; Baclofen; Cross-Over Studies; Esophageal pH Monitoring; Female; Gastroesophageal Reflux	2012
Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study. Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:9 Topics: Adult; Baclofen; Chest Pain; Double-Blind Method; Eructation; Esophageal pH Monitoring; Female; GABA	2012
The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:9 Topics: Adult; Baclofen; Cross-Over Studies; Double-Blind Method; Esophagogastric Junction; Female; Gastroes	2002
Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:2 Topics: Adolescent; Adult; Aged; Baclofen; Electric Impedance; Female; GABA Agonists; Gastric Acid; Gastric	2003
Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut, 2003, Volume: 52, Issue:4 Topics: Adult; Baclofen; Double-Blind Method; Drug Administration Schedule; Female; GABA Agonists; Gastric A	2003
Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut, 2003, Volume: 52, Issue:10 Topics: Adult; Baclofen; Chi-Square Distribution; Drug Resistance; Drug Therapy, Combination; Duodenogastric	2003
Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. The Journal of pediatrics, 2006, Volume: 149, Issue:4 Topics: Adolescent; Baclofen; Child; Child, Preschool; Double-Blind Method; Female; GABA Agonists; Gastroeso	2006
Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study. Neurogastroenterology and motility, 2008, Volume: 20, Issue:7 Topics: Adult; Baclofen; Deglutition; Double-Blind Method; Esophageal Sphincter, Lower; Female; Gastroesopha	2008
Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology, 2000, Volume: 118, Issue:1 Topics: Adolescent; Adult; Baclofen; Deglutition; Double-Blind Method; Esophagogastric Junction; Esophagus;	2000
Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut, 2002, Volume: 50, Issue:1 Topics: Adult; Aged; Analysis of Variance; Baclofen; Cross-Over Studies; Esophagogastric Junction; Female; G	2002
Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Over Studies; Double-Blind Method; Female; Gastroesopha	2002

Article	Year
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors. Journal of medicinal chemistry, 2008, Jul-24, Volume: 51, Issue:14 Topics: Animals; Dose-Response Relationship, Drug; GABA Agonists; GABA-B Receptor Agonists; Gastroesophageal	2008
Editorial: refractory reflux sensitivity - a place for baclofen? Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:4 Topics: Baclofen; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Muscle Relaxants, Central	2022
Editorial: refractory reflux sensitivity-A place for baclofen? Authors' reply. Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:4 Topics: Baclofen; Esophagitis, Peptic; Gastroesophageal Reflux; Humans	2022
Letter: should we have to include baclofen in the GORD therapy armamentarium? authors' reply. Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:8 Topics: Baclofen; Gastroesophageal Reflux; Humans	2022
Letter: should we have to include baclofen in the GORD therapy armamentarium? Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:8 Topics: Baclofen; Gastroesophageal Reflux; Humans	2022
Laparoscopic fundoplication for a child with abdominal intrathecal Baclofen pump. Asian journal of endoscopic surgery, 2020, Volume: 13, Issue:3 Topics: Baclofen; Cerebral Palsy; Child; Fundoplication; Gastroesophageal Reflux; Humans; Laparoscopy	2020
Provider Variability in the Management Patterns of Increased Nonacid Reflux. Digestive diseases and sciences, 2021, Volume: 66, Issue:4 Topics: Baclofen; Clinical Decision-Making; Cross-Sectional Studies; Electric Impedance; Esophageal pH Monit	2021
Pressure and length of the lower esophageal sphincter as predictive indicators of therapeutic efficacy of baclofen for refractory gastroesophageal reflux-induced chronic cough. Respiratory medicine, 2021, Volume: 183 Topics: Baclofen; Chronic Disease; Cough; Esophageal Sphincter, Lower; Female; Gastroesophageal Reflux; Huma	2021
White Paper AGA: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:8 Topics: Baclofen; Biopsy; Endoscopy, Gastrointestinal; Esophageal pH Monitoring; Esophagitis; Esophagogastri	2017
Editorial: breaking the cycle of cough in GERD-neuromodulators to the rescue? Authors' reply. Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:9 Topics: Baclofen; Cough; Gabapentin; Gastroesophageal Reflux; Humans; Neurotransmitter Agents	2019
Editorial: breaking the cycle of cough in GERD-neuromodulators to the rescue? Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:9 Topics: Baclofen; Cough; Gabapentin; Gastroesophageal Reflux; Humans; Neurotransmitter Agents	2019
Baclofen for the treatment of pediatric GERD. Journal of pediatric gastroenterology and nutrition, 2013, Volume: 57, Issue:6 Topics: Adolescent; Baclofen; Child; Child, Preschool; Esophageal Sphincter, Lower; Female; GABA-B Receptor	2013
Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough. World journal of gastroenterology, 2013, Jul-21, Volume: 19, Issue:27 Topics: Adult; Baclofen; Capsaicin; Cohort Studies; Cough; Domperidone; Esophageal pH Monitoring; Female; Ga	2013
Effect of baclofen on the acid pocket at the gastroesophageal junction. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2015, Volume: 28, Issue:5 Topics: Adult; Baclofen; Esophageal Sphincter, Lower; Esophagogastric Junction; Female; GABA-B Receptor Agon	2015
Comparison of clinical characteristics of chronic cough due to non-acid and acid gastroesophageal reflux. The clinical respiratory journal, 2015, Volume: 9, Issue:2 Topics: Adult; Anti-Ulcer Agents; Baclofen; Capsaicin; Chronic Disease; Cough; Domperidone; Esophageal pH Mo	2015
Pharmacologic treatments for esophageal disorders. Annals of the New York Academy of Sciences, 2014, Volume: 1325 Topics: Analgesics, Opioid; Animals; Baclofen; Enteric Nervous System; Esophageal Diseases; Gastroesophageal	2014
Baclofen and transient lower oesophageal sphincter relaxations - the band plays on. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:11-12 Topics: Baclofen; Esophageal Sphincter, Lower; Female; GABA-B Receptor Agonists; Gastroesophageal Reflux; Hu	2014
Editorial: baclofen and transient lower oesophageal sphincter relaxations - the band plays on - authors' reply. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:11-12 Topics: Baclofen; Esophageal Sphincter, Lower; Female; GABA-B Receptor Agonists; Gastroesophageal Reflux; Hu	2014
The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs. European journal of pharmacology, 2010, May-25, Volume: 634, Issue:1-3 Topics: Animals; Baclofen; Dogs; Esophagus; Female; GABA Agonists; GABA-B Receptor Agonists; Gastric Acid; G	2010
Beyond acid suppression: new pharmacologic approaches for treatment of GERD. Current gastroenterology reports, 2010, Volume: 12, Issue:3 Topics: Animals; Baclofen; Cannabinoid Receptor Agonists; Dogs; Dronabinol; Erythromycin; GABA Agonists; GAB	2010
What is nonacid reflux disease? Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2011, Volume: 25, Issue:1 Topics: Baclofen; Esophageal Sphincter, Lower; Gastroesophageal Reflux; Humans; Phosphinic Acids; Propylamin	2011
Baclofen effects on esophageal function: a possible therapy for GERD? Gastroenterology, 2002, Volume: 123, Issue:5 Topics: Baclofen; Esophagogastric Junction; Esophagus; GABA Agonists; Gastroesophageal Reflux; Humans; Muscl	2002
Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. Therapeutic drug monitoring, 2003, Volume: 25, Issue:1 Topics: Administration, Oral; Baclofen; Body Weight; Child, Preschool; Female; Gastroesophageal Reflux; Huma	2003
Impeding gastroesophageal refluxate: a new application of an old medication. Gastroenterology, 2003, Volume: 125, Issue:3 Topics: Baclofen; Electric Impedance; Esophagogastric Junction; Gastroesophageal Reflux; Humans; Hydrogen-Io	2003
Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. Journal of pediatric gastroenterology and nutrition, 2004, Volume: 38, Issue:3 Topics: Administration, Oral; Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; De Lange Syndro	2004
Persistent heartburn in a patient on proton-pump inhibitor. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:4 Topics: Acupuncture Therapy; Adult; Analgesics; Anti-Ulcer Agents; Baclofen; Bile Reflux; Bilirubin; Electri	2008
Baclofen therapy for chronic hiccup. The European respiratory journal, 1995, Volume: 8, Issue:2 Topics: Anti-Ulcer Agents; Baclofen; Chronic Disease; Cisapride; Dose-Response Relationship, Drug; Female; G	1995
Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. The American journal of physiology, 1999, Volume: 277, Issue:4 Topics: Animals; Baclofen; Behavior, Animal; Deglutition; Esophagogastric Junction; Female; Ferrets; GABA Ag	1999
Triggering of transient LES relaxations in ferrets: role of sympathetic pathways and effects of baclofen. American journal of physiology. Gastrointestinal and liver physiology, 2000, Volume: 279, Issue:1 Topics: Animals; Baclofen; Capsaicin; Eating; Esophagogastric Junction; Female; Ferrets; Gastroesophageal Re	2000
Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog. European journal of pharmacology, 2000, Sep-01, Volume: 403, Issue:1-2 Topics: Animals; Baclofen; Dogs; Dose-Response Relationship, Drug; Eating; Esophagogastric Junction; GABA Ag	2000
Anti-relaxation therapy in GORD. Gut, 2002, Volume: 50, Issue:1 Topics: Antacids; Baclofen; Esophagogastric Junction; GABA Agonists; Gastroesophageal Reflux; Humans; Treatm	2002
More pathophysiologically oriented treatment of GORD? Lancet (London, England), 2002, Apr-13, Volume: 359, Issue:9314 Topics: Animals; Baclofen; Esophagogastric Junction; GABA Agonists; Gastroesophageal Reflux; Humans	2002
Hiccups and related esophageal motor disorders. Hepato-gastroenterology, 1991, Volume: 38, Issue:5 Topics: Amantadine; Baclofen; Esophageal Motility Disorders; Esophagogastric Junction; Esophagus; Gastroesop	1991

baclofen and Gastroesophageal Reflux